Could health reform bite Lilly harder than most?-WEB ONLY
When it comes to health care reform, Eli Lilly and Co. has its derriere exposed more than its drugmaker peers. That’s according to a recent report by Jason Napodano, a senior pharmaceutical analyst at Zack’s Equity Research. In an April 9 report, he examined potential negatives in President Barack Obama’s health care reform outline. While […]